[Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial].

Li YN, Zhou LX, Qiang XH, Yu TO, Mao KJ, Feng B, Wen WB, Zou YC, Li WY, Li C

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Mar 2009Cited by 7 (Europe PMC)

PMID19278581PepBankPUB-19278581

Publisher pageAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, 28-day ventilation time, ICU stay and 28-day mortality were lower than control in all three treatment groups, but the abstract reports significant differences only for the CBP and combined groups, not for the thymosin alpha1 group.
In plain wordsIn adults with severe sepsis, ventilation time, ICU stay and deaths were lower with thymosin alpha1 than standard care, but not reported as significant.
Peptide
Thymosin alpha-1
Outcome
No significant change28-day MV time, ICU stay and 28-day mortality versus control
Study
n = 47
Comparator
Control (classical SSC therapy)
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the control group, the 28-day mechanical ventilation (MV) time, length of ICU stay, 28-day mortality of three treatment groups were decreased. There was statistically significant difference in the length of ICU stay of the CBP group, and also the 28-day MV time, length of ICU stay of t…
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858101
02HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, CD3+ T lymphocytes were significantly higher after 7 days of thymosin alpha1 than in the control group.
In plain wordsIn adults with severe sepsis, thymosin alpha1 gave higher CD3+ T cell counts after 7 days than standard care alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD3+ T lymphocytes after 7 days versus control
Study
n = 47
Comparator
Control (classical SSC therapy)
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables at the same period in the control group, only CD3(+) T lymphocytes were increased significantly after 7-day treatment in thymosin alpha1 group (P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858107
03HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, only CD3+ T lymphocytes differed significantly from control after 7 days of thymosin alpha1, so HLA-DR, CD4+ and CD8+ did not.
In plain wordsIn adults with severe sepsis, thymosin alpha1 did not significantly change HLA-DR, CD4+ or CD8+ cells compared with standard care alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeHLA-DR, CD4+ and CD8+ after 7 days versus control
Study
n = 47
Comparator
Control (classical SSC therapy)
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables at the same period in the control group, only CD3(+) T lymphocytes were increased significantly after 7-day treatment in thymosin alpha1 group (P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858108
04HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, APACHE II and Marshall scores did not differ significantly from control after 7 days of thymosin alpha1.
In plain wordsIn adults with severe sepsis, thymosin alpha1 did not significantly change illness severity scores compared with standard care alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeAPACHE II and Marshall scores after 7 days versus control
Study
n = 47
Comparator
Control (classical SSC therapy)
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables at the same period in the control group, only CD3(+) T lymphocytes were increased significantly after 7-day treatment in thymosin alpha1 group (P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858109
05HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, Marshall scores fell significantly after 7 days of thymosin alpha1 compared with before treatment.
In plain wordsIn adults with severe sepsis, organ dysfunction scores fell after 7 days of thymosin alpha1 compared with before treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseMarshall score after 7 days versus baseline
Study
n = 23
Comparator
Before treatment
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables before treatment, Marshall scores were decreased significantly and levels of HLA-DR, CD3(+), CD4(+), CD8(+)T lymphocytes were increased significantly after 7-day treatment with thymosin alpha1 group (all P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858102
06HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, HLA-DR levels rose significantly after 7 days of thymosin alpha1 compared with before treatment.
In plain wordsIn adults with severe sepsis, an immune marker (HLA-DR) rose after 7 days of thymosin alpha1 compared with before treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseHLA-DR level after 7 days versus baseline
Study
n = 23
Comparator
Before treatment
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables before treatment, Marshall scores were decreased significantly and levels of HLA-DR, CD3(+), CD4(+), CD8(+)T lymphocytes were increased significantly after 7-day treatment with thymosin alpha1 group (all P<0.05) .
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858103
07HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, CD3+ T lymphocytes rose significantly after 7 days of thymosin alpha1 compared with before treatment.
In plain wordsIn adults with severe sepsis, CD3+ T cells rose after 7 days of thymosin alpha1 compared with before treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD3+ T lymphocytes after 7 days versus baseline
Study
n = 23
Comparator
Before treatment
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables before treatment, Marshall scores were decreased significantly and levels of HLA-DR, CD3(+), CD4(+), CD8(+)T lymphocytes were increased significantly after 7-day treatment with thymosin alpha1 group (all P<0.05) .
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858104
08HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, CD4+ T lymphocytes rose significantly after 7 days of thymosin alpha1 compared with before treatment.
In plain wordsIn adults with severe sepsis, CD4+ T cells rose after 7 days of thymosin alpha1 compared with before treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD4+ T lymphocytes after 7 days versus baseline
Study
n = 23
Comparator
Before treatment
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables before treatment, Marshall scores were decreased significantly and levels of HLA-DR, CD3(+), CD4(+), CD8(+)T lymphocytes were increased significantly after 7-day treatment with thymosin alpha1 group (all P<0.05) .
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858105
09HumanRandomized controlled trialEfficacy outcome
In adults with severe sepsis, CD8+ T lymphocytes rose significantly after 7 days of thymosin alpha1 compared with before treatment.
In plain wordsIn adults with severe sepsis, CD8+ T cells rose after 7 days of thymosin alpha1 compared with before treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD8+ T lymphocytes after 7 days versus baseline
Study
n = 23
Comparator
Before treatment
Outcome group
Immune response · Immune and inflammation
Studied dose
1.6 mg · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Compared with the variables before treatment, Marshall scores were decreased significantly and levels of HLA-DR, CD3(+), CD4(+), CD8(+)T lymphocytes were increased significantly after 7-day treatment with thymosin alpha1 group (all P<0.05) .
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-one patients, age over 18 years, suffering from severe sepsis with Marshall score over 5, admitted to the intensive care unit (ICU) from June, 2004 to October, 2007, were randomly divided into four groups.
Summary · context
The group of thymosin alpha1 (23 cases) were treated with thymosin alpha1, in a dose of 1.6 mg subcutaneous injection per day for 7 days.
Report a problemFND-1927858106

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

10HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, combined CBP plus thymosin alpha1 shortened 28-day mechanical ventilation time versus control.
In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 shortened ventilator time compared with standard care alone.
Peptide
Thymosin alpha-1
Outcome
Decrease28-day MV time versus control, combined therapy
Study
n = 46
Comparator
Control (classical SSC therapy)
Outcome group
Intensive care and hospital outcomes · Whole body
Source sentences
Summary
There was statistically significant difference in the length of ICU stay of the CBP group, and also the 28-day MV time, length of ICU stay of the group of combined therapy group (all P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in the group of combined therapy (22 cases) were treated with CBP and thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858110
11HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, combined CBP plus thymosin alpha1 shortened the length of ICU stay versus control.
In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 shortened ICU stay compared with standard care alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseICU stay versus control, combined therapy
Study
n = 46
Comparator
Control (classical SSC therapy)
Outcome group
Intensive care and hospital outcomes · Whole body
Source sentences
Summary
There was statistically significant difference in the length of ICU stay of the CBP group, and also the 28-day MV time, length of ICU stay of the group of combined therapy group (all P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in the group of combined therapy (22 cases) were treated with CBP and thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858111
12HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, combined CBP plus thymosin alpha1 raised CD3+ T lymphocytes after 3 days more than thymosin alpha1 alone.
In plain wordsIn adults with severe sepsis, blood purification plus thymosin alpha1 raised CD3+ T cells at 3 days more than thymosin alpha1 alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD3+ T lymphocytes at 3 days, combined therapy versus thymosin alpha1 alone
Study
n = 45
Comparator
Thymosin alpha1 alone
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Compared with thymosin alpha1 group, all the indexes were improved but only level of CD3(+) T lymphocytes after 3-day treatment in the combined therapy group increased significantly (P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in the group of combined therapy (22 cases) were treated with CBP and thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1927858112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

[Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial].

Summary

Results from this study12

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

MeSH terms